310 related articles for article (PubMed ID: 32517716)
1. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
Taugner J; Eze C; Käsmann L; Roengvoraphoj O; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
Radiat Oncol; 2020 Jun; 15(1):148. PubMed ID: 32517716
[TBL] [Abstract][Full Text] [Related]
2. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
[TBL] [Abstract][Full Text] [Related]
3. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
4. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
5. First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
Hofstetter K; Taugner J; Käsmann L; Mansoorian S; Flörsch B; Eze C; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Strahlenther Onkol; 2024 Jul; 200(7):614-623. PubMed ID: 37975883
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M
Int J Clin Oncol; 2020 Jan; 25(1):67-73. PubMed ID: 31506751
[TBL] [Abstract][Full Text] [Related]
7. Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer.
Lee KH; Ahn YC; Pyo H; Noh JM; Park SG; Kim TG; Lee E; Nam H; Lee H; Sun JM; Ahn JS; Ahn MJ; Park K
Cancer Res Treat; 2019 Apr; 51(2):769-776. PubMed ID: 30205417
[TBL] [Abstract][Full Text] [Related]
8. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
[TBL] [Abstract][Full Text] [Related]
10. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
Topkan E; Parlak C; Kotek A; Yuksel O; Cengiz M; Ozsahin M; Pehlivan B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1264-71. PubMed ID: 22172902
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
[TBL] [Abstract][Full Text] [Related]
12. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
[TBL] [Abstract][Full Text] [Related]
13. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
14. Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
Casiraghi M; Maisonneuve P; Piperno G; Bellini R; Brambilla D; Petrella F; Marinis F; Spaggiari L
Semin Thorac Cardiovasc Surg; 2017 Summer; 29(2):233-241. PubMed ID: 28823336
[TBL] [Abstract][Full Text] [Related]
15. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer.
Ye JC; Ding L; Atay SM; Nieva JJ; McFadden PM; Chang E; Kim AW
Semin Thorac Cardiovasc Surg; 2020; 32(1):153-159. PubMed ID: 31220530
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.
Nakamichi S; Horinouchi H; Asao T; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ito Y; Watanabe SI; Ohe Y
Clin Lung Cancer; 2017 Nov; 18(6):e441-e448. PubMed ID: 28583380
[TBL] [Abstract][Full Text] [Related]
17. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
[TBL] [Abstract][Full Text] [Related]
18. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy.
Cai XW; Xu LY; Wang L; Hayman JA; Chang AC; Pickens A; Cease KB; Orringer MB; Kong FM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1100-5. PubMed ID: 19540063
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
